TCRT
NASDAQAlaunos Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.76-0.39 (-12.38%)
2026-02-272026-06-02
News · 26 weeks210%
2025-12-072026-05-31
Mix1390d
- SEC Filings6(46%)
- Insider4(31%)
- Other2(15%)
- Leadership1(8%)
Latest news
25 items- INSIDERChief Executive Officer Weis Holger was granted 3,700 shares, increasing direct ownership by 306% to 4,911 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- PRAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese miceA non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today reported an integrated preclinical readout for ALN1003, the Company's investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laborato
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- PRAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity ModelsFORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver diseas
- SECSEC Form 10-Q filed by Alaunos Therapeutics Inc.10-Q - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- PRValion Bio Appoints Melinda Lackey as General CounselSeasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership TeamSAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (NASDAQ:VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Ms. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built f
- INSIDERDirector Vieser Jaime was granted 6,515 shares, increasing direct ownership by 20% to 38,853 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Postma Robert W was granted 6,274 shares, increasing direct ownership by 14% to 50,146 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Jerman Michael Allen was granted 6,032 shares, increasing direct ownership by 63% to 15,621 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- SECAmendment: SEC Form 10-K/A filed by Alaunos Therapeutics Inc.10-K/A - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- SECSEC Form 10-K filed by Alaunos Therapeutics Inc.10-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- PRAlaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersThe lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated miceEfforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT), an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's lea
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- INSIDERDirector Vieser Jaime was granted 5,839 shares, increasing direct ownership by 22% to 32,338 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Postma Robert W was granted 5,622 shares, increasing direct ownership by 15% to 43,872 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Jerman Michael Allen was granted 5,406 shares, increasing direct ownership by 129% to 9,589 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- SECSEC Form 424B8 filed by Alaunos Therapeutics Inc.424B8 - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- INSIDERDirector Vieser Jaime was granted 5,340 shares, increasing direct ownership by 25% to 26,499 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Postma Robert W was granted 5,142 shares, increasing direct ownership by 16% to 38,250 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Jerman Michael Allen was granted 4,183 shares (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- SECSEC Form 10-Q filed by Alaunos Therapeutics Inc.10-Q - Alaunos Therapeutics, Inc. (0001107421) (Filer)
TCRT FAQ
6 questionsWhat does Alaunos Therapeutics Inc. do?
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The...Where does TCRT stock trade?
Alaunos Therapeutics Inc. (TCRT) is listed on NASDAQ.What sector and industry is TCRT in?
Alaunos Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TCRT?
Alaunos Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Wells Fargo: Overweight with a $300.00 price target on 2022-10-04. Recent price targets cluster around $300.00.What companies are similar to TCRT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TCRT side-by-side with any of them on Quantisnow.How can I track TCRT on Quantisnow?
Quantisnow aggregates Alaunos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TCRT to receive live email and push alerts on every new disclosure.